Global Infectious Disease Drug Market, By Source Type (Bacterial Diseases, Virusal Diseases, Fungal Disease, Parasitic Disease), Disease Type (Jaundice, Leprosy, Listeria, Lyme Disease, Malaria, Measles, Molluscum Contagiosum, , Norovirus, Pyelonephritis, Rabies, Severe Acute Respiratory Syndrome, Sepsis, Tetanus, West Nile, Zika, Ebola Disease, Others), Treatment Type (Medication, Dietary Supplements, Surgery), Mode of Action Type (Antibacterial Drugs, Antiviral Drugs, Antifungal Drugs, Antiparasitic Drugs), Drug Type (Tafenoquine, Omadacycline, Tecovirimat, Eravacycline, Delafloxacin, Plazomicin, Benznidazole, Secnidazole, Daclatasvir, Dalbavancin, Others), Route of Administration (Oral, Topical, Intravenous), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.
Market Analysis and Insights : Global Infectious Disease Drug Market
The infectious disease drug market is expected to gain market growth at a potential rate of 5.45% in the forecast period of 2021 to 2028. Increase in the global prevalence of infectious diseases is the vital factor escalating the market growth.
Infectious disease is defined as pathogenic microorganism disease caused by infectious agent such as bacteria, viruses, fungi and parasites. It can spread from one person to another healthy individual. People who have likely to developed weakened immune system, this could be due to drugs, age, or other diseases and people who they have not been vaccinated before are prone to the infections.
Continuous shift in focus from centralized laboratories to decentralized point-of-care testing will uplift the market growth, also rise in the growth in funding for research on infectious disease diagnostics, rise in the awareness about treatment and technological advancement, increase in the prevalence of indoor as well as outdoor infections and rise in the government initiatives programs in sanitization and regulations for food safety are some of the crucial factors among others driving the infectious disease drug market growth. Moreover, increase in the advancement in genomics and proteomics, rise in the awareness about personalized medicine and rise in the demand from emerging markets will further create new opportunities for the infectious disease drug market in the forecast period of 2021-2028.
However, inadequate reimbursements and rise in the healthcare costs limiting the use of novel diagnostic techniques are the major factors among others acting as restraints, and will further challenge the infectious disease drug market in the forecast period mentioned above.
This infectious disease drug market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis on the infectious disease drug market scenario contact Data bridge market research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Infectious Disease Drug Market Scope and Market Size
The infectious disease drug market is segmented on the basis of source type, disease type, treatment type, mode of action, drug type, route of administration and end-users. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of source type, the infectious disease drug market is segmented into bacterial diseases, virusal diseases, fungal disease and parasitic disease.
- Based on disease type, the infectious disease drug market is segmented into jaundice, leprosy, listeria, Lyme disease, malaria, measles, molluscum contagiosum, molluscum contagiosum, norovirus, pyelonephritis, rabies, severe acute respiratory syndrome, sepsis, tetanus, west Nile, zika, Ebola disease and others.
- Based on treatment type, the infectious disease drug market is segmented into medication, dietary supplements and surgery.
- Based on mode of action, the infectious disease drug market is segmented into antibacterial drugs, antiviral drugs, antifungal drugs and antiparasitic drugs.
- Based on drug type, the infectious disease drug market is segmented into tafenoquine, omadacycline, tecovirimat, eravacycline, delafloxacin, plazomicin, benznidazole, secnidazole, daclatasvir, dalbavancin and others.
- Based on route of administration, the infectious disease drug market is segmented into oral, topical and intravenous.
- The infectious disease drug market is also segmented on the basis of end-users into hospitals, homecare, specialty clinics and others.
Infectious Disease Drug Market Country Level Analysis
The infectious disease drug market is analysed and market size information is provided by country, type, drug, diagnosis, treatment and end-users as referenced above.
The countries covered in the infectious disease drug market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the infectious disease drug market due to rise in the prevalence of such disorders and favourable reimbursement scenario, rise in the growth in funding for research on infectious disease diagnostics and rise in the awareness about treatment and technological advancement in this region. Asia-Pacific is the expected region in terms of growth in infectious disease drug market due to increase in the incidence of these conditions and rising expenditure on the prevention and diagnosis of infectious diseases in this region.
The country section of the infectious disease drug market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The infectious disease drug market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Infectious Disease Drug Market Share Analysis
The infectious disease drug market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to infectious disease drug market.
The major players covered in the infectious disease drug market report are F. Hoffmann-La Roche Ltd, Gilead Sciences, Inc., GlaxoSmithKline Plc, Johnson & Johnson Private Limited, Merck & Co., Inc., Pfizer Inc., AbbVie Inc., Vertex Pharmaceuticals Incorporated, ViiV Healthcare group of companies, Sanofi S.A, Eli Lilly and Company, Novartis AG and Mitsubishi Tanabe Pharma Corporation among other domestic and global players. Infectious disease drug market share data is available for global, North America, South America, Europe, Asia-Pacific (APAC) and Middle East and Africa (MEA) separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.